A drug screening toolkit based on the -1 ribosomal frameshifting of SARS-CoV-2

  • Heliyon. 2020 Aug;6(8):e04793. doi: 10.1016/j.heliyon.2020.e04793.
Yanqiong Chen  1  2  3 ,  Huan Tao  4 ,  Silan Shen  5  3 ,  Zhiyong Miao  1  3 ,  Lili Li  5  3 ,  Yongqian Jia  4 ,  Hu Zhang  5  3 ,  Xiufeng Bai  1  3 ,  Xinyuan Fu  1  3
Affiliations
  • 1. Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, China.
  • 2. National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.
  • 3. Clinical Institute of Inflammation and Immunology (CIII), Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu 610041, China.
  • 4. Department of Hematology and Research Laboratory of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • 5. Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
PMID: 32869005 DOI: 10.1016/j.heliyon.2020.e04793
Abstract

The -1 ribosomal frameshifting is vital for the translation of the open reading frame (ORF)1b in SARS-CoV-2. The products of ORF1b participate in viral replication. Therefore, changing the frameshift frequency reduces the survival of the virus. This study aimed to successfully develop a toolkit for screening Antiviral drugs. Finally, the FDA-approved drug library was screened, revealing that ivacaftor and (-)-Huperzine A worked well in changing the -1 ribosomal frameshifting of SARS-CoV-2 in vitro.

Keywords
-1 ribosomal frameshifting; Biomedical engineering; Drug screen; Microbial biotechnology; Molecular biology; Peptides; Protein engineering; SARS-Cov-2; Virology.
Products
Inhibitors & Agonists
Other Products